Despite the limitations inherent in any long-term study ( for example , potential differences between returning and nonreturning patients ) , these results indicate that patients with relapsing-remitting multiple sclerosis can experience sustained benefit over many years from early interferon beta-1a subcutaneous therapy three times weekly compared with patients whose treatment is delayed .
